Carolyn Rebeiro from Mining.com.au sits down with ABx Group Limited (ASX:ABX) Managing Director and CEO Dr Mark Cooksey and Corporate Connect Senior Equities Analyst Richard Close for an in-depth look at the company and its value proposition.
Copyright 2023 – Finance News Network
Source: Finance News Network
17 Nov 2023 - Shaw and Partners Chief Investment Office Martin Crabb discusses when to get more bullish on equities.
Read More11 Sep 2024 - RocketDNA Limited (ASX:RKT) CEO Christopher Clark discusses how the company's AI-powered drones are revolutionising data services for sectors like mining and public safety.
Read More25 Sep 2023 - Wally Graham of Resources Roadhouse at the New World Metals Conference, speaking with Iggy Tan, Managing Director of Altech Batteries (ASX:ATC).
Read More25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.
Read More28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process timeline, with commercial sales expected in the US for 2021.
Read More23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More06 Aug 2025 - Sovereign Advisors Principal Advisor Zaheer Lalani and Investment Manager Max Riaz provide a quarterly update on the markets.
Read More05 Dec 2019 - Bio-Gene Technology Limited (ASX:BGT) CEO, Richard Jagger discusses the company's novel suite of insecticides, progress with trials and market opportunity.
Read More11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
Read More
